Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Fiche publication
Date publication
janvier 2022
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J
Lien Pubmed
Résumé
Exit strategy after natalizumab cessation in multiple sclerosis (MS) is a crucial point because the risk of disease reactivation is high during this period. The objective of this observational study was to compare ocrelizumab to fingolimod after natalizumab cessation in patients with relapsing-remitting multiple sclerosis (RRMS).
Mots clés
Fingolimod, Multiple sclerosis, Natalizumab, Ocrelizumab, Switch
Référence
J Neurol. 2022 Jan 4;: